A detailed history of Morgan Stanley transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,664,169 shares of CHRS stock, worth $4.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,664,169
Previous 2,069,853 28.71%
Holding current value
$4.61 Million
Previous $6.89 Million 7.62%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.02 - $3.14 $1.2 Million - $1.87 Million
594,316 Added 28.71%
2,664,169 $6.37 Million
Q4 2023

Feb 13, 2024

SELL
$1.59 - $3.85 $1.86 Million - $4.51 Million
-1,172,374 Reduced 36.16%
2,069,853 $6.89 Million
Q3 2023

Nov 15, 2023

BUY
$3.74 - $5.45 $849,380 - $1.24 Million
227,107 Added 7.53%
3,242,227 $12.1 Million
Q2 2023

Aug 14, 2023

BUY
$3.79 - $8.3 $9.5 Million - $20.8 Million
2,505,776 Added 491.96%
3,015,120 $12.9 Million
Q1 2023

May 15, 2023

SELL
$5.89 - $10.52 $1.21 Million - $2.15 Million
-204,647 Reduced 28.66%
509,344 $3.48 Million
Q4 2022

Feb 14, 2023

BUY
$5.69 - $10.07 $73,759 - $130,537
12,963 Added 1.85%
713,991 $5.65 Million
Q3 2022

Nov 14, 2022

SELL
$7.17 - $13.87 $803,814 - $1.55 Million
-112,108 Reduced 13.79%
701,028 $6.74 Million
Q2 2022

Oct 27, 2022

BUY
$5.86 - $13.23 $1.33 Million - $3 Million
227,083 Added 38.75%
813,136 $5.89 Million
Q2 2022

Aug 15, 2022

BUY
$5.86 - $13.23 $1.33 Million - $3 Million
227,083 Added 38.75%
813,136 $5.89 Million
Q1 2022

Oct 27, 2022

SELL
$10.92 - $16.41 $2.48 Million - $3.73 Million
-227,083 Reduced 27.93%
586,053 $7.57 Million
Q1 2022

May 13, 2022

BUY
$10.92 - $16.41 $2 Million - $3 Million
182,755 Added 45.32%
586,053 $7.57 Million
Q4 2021

Feb 14, 2022

SELL
$15.81 - $18.99 $434,237 - $521,579
-27,466 Reduced 6.38%
403,298 $6.44 Million
Q3 2021

Nov 15, 2021

BUY
$12.68 - $17.79 $5.46 Million - $7.66 Million
430,764 New
430,764 $6.92 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $134M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.